70.0 B
Thymosin Beta-4
Also known as: TB-500, TB4
Strong Clinical Evidence Category 2 Restricted
Research Evidence 90.0/100
Safety Profile 50.0/100
21 Clinical Trials
PHASE4: 1 PHASE3: 4 PHASE2, PHASE3: 1 PHASE2: 9 PHASE1, PHASE2: 1 PHASE1: 4 NA: 1
- Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment PHASE4 TERMINATED Prof JMA Lange
- Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 PHASE3 RECRUITING ReGenTree, LLC
- Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 PHASE3 COMPLETED ReGenTree, LLC
- Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2 PHASE3 COMPLETED ReGenTree, LLC
- A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma PHASE3 COMPLETED AstraZeneca
Showing 5 of 21 trials.
20 Research Papers
- Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res unknown
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med Review
- Comparative Proteomic Analysis of the Secretome of Control and BRAF/MEK Inhibitor-Resistant Melanoma Cells. J Proteome Res unknown
- Rich-Defect Ru-Tb(2)Ce(2)O(7+x) Catalysts for Highly Efficient Soot Particulate Elimination: Insights into the key roles of Ru-O-Ce/Tb Interfacial Bonds, Ru(0) Sites, and Surface Vacancies. Environ Sci Technol unknown
- Tetrametallic Terbium/Europium Fluorenylphosphonate With Excellent X-Ray Scintillating and Photo-Induced Luminescence. Chemistry unknown
Showing 5 of 20 papers by citation count.
FDA Data
Not FDA-Approved
Thymosin Beta-4 has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.
This peptide is classified as FDA Category 2 — it is prohibited from use in compounding pharmacies effective 2024. Obtaining it requires unregulated sources.
Frequently Asked Questions
Is Thymosin Beta-4 FDA approved?
No, Thymosin Beta-4 is not FDA approved. It is classified as FDA Category 2 and is banned from compounding pharmacies.
How many clinical trials has Thymosin Beta-4 been studied in?
Thymosin Beta-4 has been studied in 21 registered clinical trials. CheckPeptides tracks phase, status, and sponsor data for each trial.
What is the trust score for Thymosin Beta-4?
Thymosin Beta-4 has a CheckPeptides trust score of 70.0/100 (grade: B). This score is based on clinical trial volume, research paper quality, FDA data, and evidence classification.
Last verified: April 7, 2026
Quick Facts
- Classification
- Actin-sequestering peptide
- Molecular Weight
- 4963.0 Da
- PubChem
- CID 45382195 ↗
- Regulatory Status
- N/A
Score Breakdown
Research Evidence 90.0/100
Safety Profile 50.0/100
Evidence Summary
- Clinical Trials
- 21
- Research Papers
- 20
- Trust Score
- 70.0/100
- Grade
- B